NCT03690141 2024-06-21
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
Effector Therapeutics
Phase 2 Terminated
Clinical Trials
5 trialsNCT04622007 2024-04-30
KICKSTART
Effector Therapeutics
Phase 2 Active not recruiting
NCT03616834 2023-03-22
Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy
Effector Therapeutics
Phase 2 Completed
NCT03258398 2019-07-18
A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer
Effector Therapeutics
Phase 2 Completed
NCT03318562 2019-07-18
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
Effector Therapeutics
Phase 2 Terminated